Cellerant Therapeutics, Inc.

SAN CARLOS, CA · Biotech · Defunct

Myeloid progenitor cells (MPC) produced by ex vivo expansion for tolerance induction in organ transplantation

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cellerant.com

Sector: Biotech
Headquarters: SAN CARLOS, CA
Latest Form D: $2M, Apr 2016
Total capital: $197M

Federal grants: $1.7M; 2 awards · 2018; Rank in peer group#133 of 326
Private capital raised: $10.4M; 6 Form D · last Apr 2016; 126 months since last filing
Federal contracts: $185M; 5 awards · Health and Human S; Rank in Biotech#6 of 4373
Granted patents: 13; 27 pending · first 2014; Rank in peer group#20 of 326

Capital timeline

Latest events

Dec 2018Federal grantHealth and Human S · Phase II · Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation$544K
Jan 2018Federal grantHealth and Human S · Phase II · Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation$1.1M
Sep 2016Federal contractHealth and Human S · Igf::ot::igf: SBIR Phase II, Topic 326: Development Of Novel Therapeutic Agents That Target Cancer Stem Cells$1.5M
Apr 2016Private capital raisedForm D · SEC · 6th filing$2M
Sep 2014Federal contractHealth and Human S · Igf::ot::igf Other Function: Development Of IL1RAP Antibodies Targeting Aml Cs$224K
Jan 2014Private capital raisedForm D · SEC · 5th filing$2.2M
Sep 2012Private capital raisedForm D · SEC · 4th filing$2.1M
Aug 2011Private capital raisedForm D · SEC · 3rd filing$800K
Dec 2010Private capital raisedForm D · SEC · 2nd filing$1M
Feb 2010Private capital raisedForm D · SEC · 1st filing$2.3M

Show 3 earlier federal awards

Sep 2012Federal contractHealth and Human S · Igf::ot::igf Other Functions - R&d Biomedical (basic Research)$1.7M
Aug 2010Federal contractHealth and Human S · Advanced Development Of Therapeutics For Treating Neutropenia Resulting From Acute Exposure To Ionizing Radiation Can 1990987 Can 1990087$170M
Sep 2008Federal contractHealth and Human S · Develop Therapy For Hematopoetic Syndrome Resulting From Acute Radiation Exposure$11.9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

17months

from Cellerant Therapeutics, Inc.’s first federal award to its first private round.

First federal award · Sep 2008: Health and Human S · $11.9M
First Form D · Feb 2010: $2.3M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grants#133 · top 41%
Granted patents#20 · top 6%
Linked publications#27 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Antoun G. NabhanDirectorNamed in SEC Form D filings
Gisela SchwabDirectorNamed in SEC Form D filings
Lowell G. SearsDirectorNamed in SEC Form D filings
Ramkumar MandalamExecutive Officer, DirectorNamed in SEC Form D filings
Richard ChyetteDirectorNamed in SEC Form D filings
Richard G. RathmannDirectorNamed in SEC Form D filings

Show all 9 people

Robby HogleDirectorNamed in SEC Form D filings
Rodney YoungExecutive OfficerNamed in SEC Form D filings
Stephen G. GreenbergDirectorNamed in SEC Form D filings

What it has protected

USPTO · 13 granted of 40

Mar 3, 2022PendingMethods Of Expanding Myeloid Cell Populations And Uses ThereofUSPTOApplication 17499809
Jul 27, 2021GrantedHumanized ANTI-CLL-1 AntibodiesUSPTOUS 11,072,662
Jan 26, 2021GrantedIsoquinolidinobenzodiazepinesUSPTOUS 10,898,580

Show all 40 patent records

Methods Of Expanding Myeloid Cell Populations And Uses ThereofMar 3, 2022 · Application 17499809Pending
Humanized ANTI-CLL-1 AntibodiesJul 27, 2021 · US 11,072,662Granted
IsoquinolidinobenzodiazepinesJan 26, 2021 · US 10,898,580Granted
Antibodies Specific For CLL-1Jul 28, 2020 · US 10,723,805Granted
Isoquinolidinobenzodiazepine (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (cbi) DimersFeb 27, 2020 · Application 16455269Pending
Methods Of Expanding Myeloid Cell Populations And Uses ThereofAug 8, 2019 · Application 16272947Pending
Isoquinolidinobenzodiazepine (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (cbi) DimersJul 16, 2019 · US 10,350,218Granted
Antibodies That Specifically Bind To TIM3May 28, 2019 · US 10,301,394Granted
Methods Of Expanding Myeloid Cell Populations And Uses ThereofApr 16, 2019 · US 10,260,044Granted
Cysteine-substituted ImmunoglobulinsNov 1, 2018 · Application 15745351Pending
IsoquinolidinobenzodiazepinesMay 22, 2018 · US 9,974,864Granted
Antibodies Specific For CLL-1Dec 26, 2017 · US 9,850,314Granted
Antibodies That Specifically Bind To TIM3Apr 25, 2017 · US 9,631,026Granted
IsoquinolidinobenzodiazepinesNov 29, 2016 · US 9,504,694Granted
Cytokine Receptors Associated With Myelogenous Haematological Proliferative Disorders And Uses ThereofJun 21, 2016 · US 9,371,390Granted
Antibodies That Bind Membrane-bound IL1RAPNov 5, 2015 · Application 14652925Pending
Antibodies Specific For CLL-1Oct 20, 2015 · US 9,163,090Granted
Methods Of Expanding Myeloid Cell Populations And Uses ThereofDec 25, 2014 · Application 14481715Pending
Compositions And Methods For Treating Haematological Proliferative Disorders Of Myeloid OriginMay 6, 2014 · US 8,715,619Granted
Anti-IL1-Rap AntibodiesApplication 62408807Pending
Isoquinolidino-duocarmycin DimersApplication 62406077Pending
Cysteine-substituted ImmunoglobulinsApplication PCTUS2016042645Pending
Chimeric Antigen Receptors With CTLA4 Signal Transduction DomainsApplication PCTUS2016030834Pending
IsoquinolidinobenzodiazepinesApplication PCTUS2016022961Pending
ANTI-IL1-RAP AntibodiesApplication PCTUS2017056808Pending
IsoquinolidinobenzodiazepinesApplication 62278934Pending
Humanized ANTI-CLL-1 AntibodiesApplication 62259100Pending
Ipsc-derived, Hypoimmunogenic, Myeloid Progenitor CellsApplication 62903911Pending
Cysteine-substituted ImmunoglobulinsApplication 62193531Pending
IsoquinolidinobenzodiazepinesApplication 62135380Pending
Ipsc-derived, Hypoimmunogenic, Myeloid Progenitor CellsApplication PCTUS2020051889Pending
Antibodies That Bind Membrane-bound IL1RAPApplication PCTUS2013077323Pending
Antibodies Specific For CLL-1Application PCTUS2013039645Pending
Megakaryocyte Progenitor Cells For Production Of PlateletsApplication PCTUS2012045781Pending
Antibodies That Specifically Bind To TIM3Application PCTUS2012045102Pending
Cytokine Receptors Associated With Myelogenous Haematological Proliferative Disorders And Uses ThereofApplication PCTUS2009038459Pending
Immunoglobulin And/or Toll-like Receptor Proteins Associated With Myelogenous Haematological Proliferative Disorders And Uses ThereofApplication PCTUS2009038462Pending
G Coupled Protein Receptors Associated With Myelogenous Haematological Proliferative Disorders And Uses ThereofApplication PCTUS2009038455Pending
Methods And Compositions For Treating Systemic Lupus ErythematosusApplication PCTUS2007086861Pending
Portable Platform Cytometric System With Isolation ChamberApplication PCTUS2007067831Pending

Recent research by its founders

ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies202514 cites
265 ADI-925: an allogeneic off-the-shelf chimeric adapter (CAd) γδ T cell therapy targeting NKG2D ligand-expressing cancers20230 cites
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models2022113 cites

VENATORX PHARMACEUTICALS INCSimilar federal contract value in Biotech · $270M in contracts
AchaogenSimilar federal contract value in Biotech · $214M in contracts
Ginkgo BioworksSimilar federal contract value in Biotech · $191M in contracts
Sarepta TherapeuticsSimilar federal contract value in Biotech · $169M in contracts
CELLPHIRE, INCSimilar federal contract value in Biotech · $162M in contracts
VEDANTA BIOSCIENCES, INC.Similar federal contract value in Biotech · $99.1M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.